Filipina - Inggeris - FDA (Food And Drug Administration)

uniqure pharma inc.; distributor: uniqure pharma inc. - iron , folic acid - tablet - 200mg (equi. to 65mg elemental iron) 400mcg

Filipina - Inggeris - FDA (Food And Drug Administration)

uniqure pharma inc.; distributor: uniqure pharma inc. - iron , folic acid - tablet - 200mg (equi. to 65mg elemental iron) 400mcg

Filipina - Inggeris - FDA (Food And Drug Administration)

n/a; importer: mylan philippines inc.; distributor: mylan philippines inc. - iron sucrose - solution for injection (i.v.) - 363.64 mg/ml (equivalent to 20 mg elemental iron)

Filipina - Inggeris - FDA (Food And Drug Administration)

unilab, inc. - vitamin b-complex , iron , lysine , buclizine hydrochloride - syrup - each 5 ml contains: thiamine hydrochloride (vitamin b1) 10 mg pyridoxine hydrochloride (vitamin b6) 5 mg cyanocobalamin (vitamin b12) 10 mcg elemental iron (as ferrous sulfate 50 mg) 10 mg l-lysine hydrochloride 125 mg buclizine hydrochloride 5 mg

Filipina - Inggeris - FDA (Food And Drug Administration)

san miguel foods, inc. - iron dextran (eq. to 200mg elemental iron) (vet.) - sterile solution for injection (im) (vet.) - 200 mg/ml

Filipina - Inggeris - FDA (Food And Drug Administration)

atc health care international corp. - iron , folic acid , vitamin b-complex - capsule - elemental iron 91.50 mg, folic acid 1 mg, vitamin b1 15 mg, vitamin b2 10 mg, vitamin b6 10 mg and vitamin b12 10 mcg

Bangladesh - Inggeris - DGDA (Directorate General of Drug Administration)

incepta pharmaceuticals ltd. - elemental iron + folic acid - tablet - 60 mg + 400 mcg

Filipina - Inggeris - FDA (Food And Drug Administration)

united laboratories, inc. - buclizine hc1 25 mg; pyridoxine hc1 5 mg; iron, elemental (as ferrous fumarate; 76 mg) 25 mg; : thiamine mononitrate 10 mg; cyanocobalamin 10 mc - capsule - each capsule contains: buclizine hc1 25 mg; pyridoxine hc1 5 mg; iron, elemental (as ferrous fumarate; 76 mg) 25 mg; : thiamine mononitrate 10 mg; cyanocobalamin 10 mcg

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

actavis pharma, inc. - iron dextran (unii: 95hr524n2m) (ferric cation - unii:91o4lml611) - ferric cation 50 mg in 1 ml - infed is indicated for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or have had an unsatisfactory response to oral iron. infed is contraindicated in patients who have demonstrated a previous hypersensitivity to iron dextran [see warnings and precautions ( 5.1 ) ] . risk summary   parenteral iron administration may be associated with hypersensitivity reactions [see warnings and precautions ( 5.1 )] , which may have serious consequences, such as fetal bradycardia (see clinical considerations). advise pregnant persons of the potential risk to the fetus. available data from postmarketing reports with iron dextran use in pregnancy are insufficient to assess the risk of major birth defects or miscarriage. there are risks to the pregnant person and fetus associated with untreated iron deficiency anemia in pregnancy (see clinical considerations). iron dextran has been shown to be teratogenic and embryocidal in mice, rats, rabbi

Amerika Syarikat - Inggeris - NLM (National Library of Medicine)

allergan, inc. - iron dextran (unii: 95hr524n2m) (ferric cation - unii:91o4lml611) - ferric cation 50 mg in 1 ml - infed is indicated for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or have had an unsatisfactory response to oral iron. infed is contraindicated in patients who have demonstrated a previous hypersensitivity to iron dextran [see warnings and precautions ( 5.1 ) ] . risk summary   parenteral iron administration may be associated with hypersensitivity reactions [see warnings and precautions ( 5.1 )] , which may have serious consequences, such as fetal bradycardia (see clinical considerations). advise pregnant persons of the potential risk to the fetus. available data from postmarketing reports with iron dextran use in pregnancy are insufficient to assess the risk of major birth defects or miscarriage. there are risks to the pregnant person and fetus associated with untreated iron deficiency anemia in pregnancy (see clinical considerations). iron dextran has been shown to be teratogenic and embryocidal in mice, rats, rabbits, dogs, and monkeys when given in doses of about 3 times the maximum human dose. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations   disease-associated maternal and/or embryo/fetal risk    untreated iron deficiency anemia (ida) in pregnancy is associated with adverse maternal outcomes such as post-partum anemia. adverse pregnancy outcomes associated with ida include increased risk for preterm delivery and low birth weight. fetal /neonatal adverse reactions severe adverse reactions including circulatory failure (severe hypotension, shock including in the context of anaphylactic reaction) may occur in pregnant persons with intravenous iron administration (such as infed) which may have serious consequences on the fetus such as fetal bradycardia, especially during the second and third trimester. data animal data no consistent adverse fetal effects were observed in mice, rats, rabbits, dogs, and monkeys at doses of 50 mg iron/kg or less. fetal and maternal toxicity has been reported in monkeys at a total intravenous dose of 90 mg iron/kg over a 14 day period. similar effects were observed in mice and rats on administration of a single dose of 125 mg iron/kg. fetal abnormalities in rats and dogs were observed at doses of 250 mg iron/kg and higher. the animals used in these tests were not iron deficient. risk summary trace amounts of unmetabolized iron dextran are present in human milk. there are no data on the effects of iron dextran in breastfed infants or effects on milk production. the development and health benefits of breastfeeding should be considered along with the mother’s clinical need for infed in addition to any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition. infed is not recommended for use in infants under 4 months of age [s ee dosage and administration ( 2.2 ) ]. reports in the literature from countries outside the united states (in particular, new zealand) have suggested that the use of intramuscular iron dextran in neonates has been associated with an increased incidence of gram-negative sepsis, primarily due to e. coli.